FDA Issues Black Box Warning for Uloric
In February 2019, the FDA issued a “black box warning” – the agency’s strongest and most prominent advisory — for Takeda’s popular gout drug, Uloric. According to health regulators, Uloric (febuxostat) is associated with an “increased risk of heart-related death and death from all causes” compared to the gout medication allopurinol. The boxed warning also… read more
Infection After Taking Xeljanz? Here’s What To Do!
Designed to treat rheumatoid arthritis and ulcerative colitis, Pfizer’s Xeljanz (tofacitinib) has been linked with potentially deadly side effects, which include: Liver enzyme elevations, lipid elevations, anemia, neutropenia, and lymphocyte abnormalities Increased risk of blood clots in the lungs, causing death Perforations of the stomach or intestines Lymphoma and other cancers Non-melanoma skin cancers Hypersensitivity… read more
New Studies Raise Questions About Quality of Drug & Medical Device Testing
In medical device and pharmaceutical lawsuits, plaintiffs often allege that the product manufacturer conducted inadequate testing on its product before releasing it on the market. Plaintiffs also claim that the manufacturer failed to conduct adequate post-approval studies to identify and prevent serious side effects. Now, a recent study published in a prominent medical journal lends… read more